The disorder is called immune thrombocytopenia, or ITP. In simple terms, the body’s immune system mistakenly attacks and destroys its own platelets.
Platelets are the tiny cells that help your blood clot. Without enough of them, a person can bruise easily and bleed for longer than normal.
In children, ITP is the most common acquired bleeding disorder. While many cases resolve on their own, some are persistent. When first-line therapies like steroids don’t work or stop working, families and doctors face a tough challenge.
The goal is to keep platelet counts in a safe range to prevent serious bleeding. This often involves trying different medications, some with difficult side effects.
The Surprising Shift
The old approach for stubborn ITP often involved stronger immune-suppressing drugs or frequent injections. These can be hard on a child’s body and family’s routine.
The new way focuses on a different biological lever. Instead of just trying to stop the immune attack, this new pill tells the bone marrow to make more platelets.
Think of it like a factory. In ITP, the immune system is destroying the factory’s product (platelets) faster than it can be made. This medication sends a direct signal to the factory foreman: “Increase production.”
The drug is called hetrombopag. It belongs to a class known as TPO receptor agonists.
Here’s a simple analogy. Your bone marrow has “docking stations” (receptors) for a natural hormone that says “make platelets.” In some kids with ITP, that signal isn’t strong enough.
Hetrombopag acts like a master key. It docks at that station and turns the platelet-production signal to “on.” This helps the bone marrow pump out more platelets to overcome the immune system’s destruction.
A Snapshot of the Trial
Researchers conducted a rigorous Phase 3 trial involving 88 children and adolescents, aged 6 to 17, with persistent ITP. For 12 weeks, two-thirds took the daily pill, and one-third took a placebo (a dummy pill). Neither the families nor the doctors knew who got which.
This was followed by another 12 weeks where all children could receive the active drug.
The results were striking. After 10 weeks, over 60% of children on hetrombopag achieved the target safe platelet count. In the placebo group, less than 10% did.
Even more important for daily life, the response was often sustained. Nearly 44% of kids on the drug maintained a safe platelet count for at least 6 straight weeks without needing emergency “rescue” therapy. In the placebo group, that sustained response rate was 0%.
The Real-World Impact
This is where the findings get practical. Needing rescue therapy—like extra steroids or immunoglobulin infusions—often means a trip to the clinic or hospital. It’s disruptive and stressful.
The study showed the pill cut the need for this rescue therapy by more than half compared to placebo.
But there is a catch.
Expert Perspective on Safety
The medication’s safety profile was generally acceptable, especially for a condition that itself carries risks. The most common side effects were things like upper respiratory infections, which were also common in the placebo group.
However, doctors paid close attention to the liver. A notable number of children (about 17.5% over 24 weeks) showed mild to moderate elevations in liver enzymes. This is a known effect of this drug class.
Critically, in this trial, none of these liver changes were severe. No child had to stop taking the drug because of it. Still, it means children on this treatment would need regular blood tests to monitor their liver health.
This does not mean the pill is available at your pharmacy today. Hetrombopag is approved for adults with certain blood disorders in some countries, but it is not yet approved for children with ITP anywhere.
This study is a major step toward that goal. It provides the high-quality evidence needed for drug regulators to review and potentially approve it for pediatric use.
If your child has persistent ITP, talk to their hematologist (blood specialist) about all treatment options. You can mention this study and ask about the class of drugs called TPO receptor agonists, which includes other approved oral medications.
Understanding the Limits
This was a well-run trial, but it has limitations. It was relatively small (88 patients) and lasted 6 months. We need larger, longer studies to fully understand the long-term safety and effectiveness in children.
Also, the study did not compare hetrombopag directly to other existing platelet-boosting drugs. We don’t yet know if it’s better, just that it’s effective.
The positive results from this Phase 3 trial will be submitted to health authorities like the U.S. FDA and the European Medicines Agency. The approval process is meticulous and can take many months.
Researchers will also continue to follow these children to gather long-term data. The journey from a successful clinical trial to a widely available prescription is a marathon, not a sprint. But for families seeking more options, this study marks a promising and significant milestone.
